Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

NCT01723228 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.

NCT NCT01723228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01723228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2012
Completion date
January 31, 2015
Enrollment
170 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease